Windlas Biotech IPO Subscription Day-2
The Rs.401.54 crore IPO of Windlas Biotech, consisting of Rs.165 crore fresh issue and Rs.236.54 crore OFS, had been fully subscribed on Day-1 itself. As per the combined bid details put out by the BSE, Windlas Biotech IPO was subscribed 7.06X overall, with bulk of the demand coming from the retail segment followed by HNI segment.
As of close of 05 August, out of the 61.36 lakh shares on offer in the IPO, Windlas Biotech saw applications for 429.22 lakh shares. This implies an overall subscription of 7.06X. The granular break-up of subscriptions were tilted in favour of retail investors but HNI and QIB bids typically come in on the last day.
Windlas Biotech IPO Subscription Status
|Qualified Institutional (QIB)||0.04 Times|
|Non-Institutional (NII)||1.12 Times|
|Retail Individual||13.52 Times|
The QIB subscription remained marginal at the end of Day-2. On 03 August, Windlas Biotech did an anchor placement of Rs.120.46 crore to 22 QIB investors including Macquarie, Optimix, Invesco, Kubera, Elara, Avendus etc. The QIB portion (net of anchor allocation) has a quota of 17.24 lakh shares of which it has got bids for just 0.70 lakh shares, implying a subscription ratio of 0.04X for QIBs at the end of Day-2.
The HNI portion got subscribed 1.12X (getting applications for 14.70 lakh shares against the quota of 13.24 lakh shares). Bulk of the funded applications and corporate applications, come in on the last day.
The retail portion is subscribed 13.52X at the end of Day-2, showing strong retail appetite. For retail investors; out of the 30.89 lakh shares on offer, valid bids were received for 413.82 lakh shares, of which bids for 319.12 lakh shares were at the cut-off price. The IPO is priced in the band of (Rs.448-Rs.460) and will close for subscription on 06 August.
Start Investing Now!
Open Free Demat Account in 5 mins